Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report) and Corvus Pharmaceuticals (CRVS – Research Report).
Insulet (PODD)
BTIG analyst Marie Thibault reiterated a Buy rating on Insulet yesterday and set a price target of $320.00. The company’s shares closed last Thursday at $255.35.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
Currently, the analyst consensus on Insulet is a Moderate Buy with an average price target of $287.58, implying a 9.6% upside from current levels. In a report released yesterday, Piper Sandler also upgraded the stock to Buy with a $340.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Corvus Pharmaceuticals (CRVS)
Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Corvus Pharmaceuticals yesterday and set a price target of $3.50. The company’s shares closed last Thursday at $0.86, close to its 52-week low of $0.70.
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Corvus Pharmaceuticals with a $3.17 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PODD:
- BigCommerce Holdings (BIGC) Gets a Hold from Oppenheimer
- Antero Resources (NYSE:AR) Has an Incredible Outlook. Should You Buy?
- Mizuho Securities Sticks to Its Buy Rating for Karuna Therapeutics (KRTX)
- Rosenblatt Securities Sticks to Their Buy Rating for Ansys (ANSS)
- Microchip (MCHP): New Buy Recommendation for This Technology Giant
